Ricardo Lauzurica
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ricardo Lauzurica has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Josep Bonet
Universitat Autònoma de Barcelona, 08193, Bellaterra, Cerdanyola del Vallès, Spain
5 shared publications Francisco Javier Juega-Mariño
3 shared publicationsI. Bancu
Nephrology Department of the University Hospital "Germans Trias I Pujol", Badalona, Spain
3 shared publicationsJ. Bonet
Department of Nephrology, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; REDinREN 12/0021/0027, Spain
3 shared publications- Javier Juega
Neprhology service, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, Spain
3 shared publications L. Cañas
Nephrology Department of the University Hospital "GermansTrias I Pujol", Badalona, Spain; REDinREN 12/0021/0027, Fundación Jiménez Díaz Hospital, Madrid, Spain
3 shared publications
Latest Publications
- Open Access
- 14 October 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (20) , 7569
Proteomic Characterization of Urinary Extracellular Vesicles from Kidney-Transplanted Patients Treated with Calcineurin Inhibitors
Use of immunosuppressive drugs is still unavoidable in kidney-transplanted patients. Since their discovery, calcineurin inhibitors (CNI) have been considered the first-line immunosuppressive agents, in spite of their known nephrotoxicity. Chronic CNI toxicity (CNIT) may lead to kidney fibrosis, a threatening scenario for graft survival. However, there is still controversy regarding CNIT diagnosis, monitoring and therapeutic management, and their specific effects at the molecular level are not fully known. Aiming to better characterize CNIT patients, in the present study, we collected urine from kidney-transplanted patients treated with CNI who (i) had a normal kidney function, (ii) suffered CNIT, or (iii) presented interstitial fibrosis and tubular atrophy (IFTA). Urinary extracellular vesicles (uEV) were enriched and the proteome was analyzed to get insight into changes happening during CNI. Members of the uroplakin and plakin families were significantly upregulated in the CNIT group, suggesting an important role in CNIT processes. Although biomarkers cannot be asserted from this single pilot study, our results evidence the potential of uEV as a source of non-invasive protein biomarkers for a better detection and monitoring of this renal alteration in kidney-transplanted patients.
- 14 October 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (20) , 7569
Open AccessProteomic Characterization of Urinary Extracellular Vesicles from Kidney-Transplanted Patients Treated with Calcineurin Inhibitors
Use of immunosuppressive drugs is still unavoidable in kidney-transplanted patients. Since their discovery, calcineurin inhibitors (CNI) have been considered the first-line immunosuppressive agents, in spite of their known nephrotoxicity. Chronic CNI toxicity (CNIT) may lead to kidney fibrosis, a threatening scenario for graft survival. However, there is still controversy regarding CNIT diagnosis, monitoring and therapeutic management, and their specific effects at the molecular level are not fully known. Aiming to better characterize CNIT patients, in the present study, we collected urine from kidney-transplanted patients treated with CNI who (i) had a normal kidney function, (ii) suffered CNIT, or (iii) presented interstitial fibrosis and tubular atrophy (IFTA). Urinary extracellular vesicles (uEV) were enriched and the proteome was analyzed to get insight into changes happening during CNI. Members of the uroplakin and plakin families were significantly upregulated in the CNIT group, suggesting an important role in CNIT processes. Although biomarkers cannot be asserted from this single pilot study, our results evidence the potential of uEV as a source of non-invasive protein biomarkers for a better detection and monitoring of this renal alteration in kidney-transplanted patients.
- Open Access
- 31 July 2018
- Published by Springer Nature in BMC Nephrology
- Vol. 19 (1) , 1-11
Molecular profile of urine extracellular vesicles from normo-functional kidneys reveal minimal differences between living and deceased donors
Kidney transplantation (KTx) is the best therapeutic approach for chronic kidney diseases leading to irreversible kidney failure. Considering the origin of the graft, several studies have reported differences between living (LD) and deceased donors (DD) in graft and patient survival. These differences seem to be related to multiple factors including, donor age and time of cold ischemia among others. Many of transplanted organs come from old-aged DDs, in which pre-transplant biopsy is recommended. However, kidney biopsy has several limitations, and there is a need to develop alternatives to assess the status of a kidney before transplantation. As the analysis of urinary extracellular vesicles (uEVs) rendered promising results as non-invasive biomarkers of kidney-related pathologies, this pilot study aimed to investigate whether profiling uEVs of LDs and DDs may be of help to assess the quality of the kidney before nephrectomy. uEVs from 5 living donors and 7 deceased donors were isolated by size-exclusion chromatography, and their protein and miRNA content were analysed by liquid chromatography followed by mass spectrometry and next generation sequencing, respectively. Then, hierarchical clustering and venn diagrams were done with Perseus software and InteractiVenn tool. Specific EVs data bases were also used for Gene Ontology analysis. Next generation sequencing revealed that uEVs from DDs contained less miRNAs than LDs, but most of the DD-expressed miRNAs were shared with LDs (96%). Only miR-326 (targeting the apoptotic-related Bcl2) was found significantly over-represented in LD. Focusing on the protein content, we detected a low intra-group correlation in both types of donors. Despite these differences, hierarchical clustering of either miRNA or protein data could not identify a differential profile between LDs and DDs. Of note, 90% of transplanted patients had a functional graft after a year from KTx. In this pilot study we found that, in normo-functional grafts, minor differences in uEVs profile could not discriminate between LDs and DDs.
- 31 July 2018
- Published by Springer Nature in BMC Nephrology
- Vol. 19 (1) , 1-11
Open AccessMolecular profile of urine extracellular vesicles from normo-functional kidneys reveal minimal differences between living and deceased donors
Kidney transplantation (KTx) is the best therapeutic approach for chronic kidney diseases leading to irreversible kidney failure. Considering the origin of the graft, several studies have reported differences between living (LD) and deceased donors (DD) in graft and patient survival. These differences seem to be related to multiple factors including, donor age and time of cold ischemia among others. Many of transplanted organs come from old-aged DDs, in which pre-transplant biopsy is recommended. However, kidney biopsy has several limitations, and there is a need to develop alternatives to assess the status of a kidney before transplantation. As the analysis of urinary extracellular vesicles (uEVs) rendered promising results as non-invasive biomarkers of kidney-related pathologies, this pilot study aimed to investigate whether profiling uEVs of LDs and DDs may be of help to assess the quality of the kidney before nephrectomy. uEVs from 5 living donors and 7 deceased donors were isolated by size-exclusion chromatography, and their protein and miRNA content were analysed by liquid chromatography followed by mass spectrometry and next generation sequencing, respectively. Then, hierarchical clustering and venn diagrams were done with Perseus software and InteractiVenn tool. Specific EVs data bases were also used for Gene Ontology analysis. Next generation sequencing revealed that uEVs from DDs contained less miRNAs than LDs, but most of the DD-expressed miRNAs were shared with LDs (96%). Only miR-326 (targeting the apoptotic-related Bcl2) was found significantly over-represented in LD. Focusing on the protein content, we detected a low intra-group correlation in both types of donors. Despite these differences, hierarchical clustering of either miRNA or protein data could not identify a differential profile between LDs and DDs. Of note, 90% of transplanted patients had a functional graft after a year from KTx. In this pilot study we found that, in normo-functional grafts, minor differences in uEVs profile could not discriminate between LDs and DDs.
- Open Access
- 1 May 2016
- Published by Elsevier in Nefrología (English Edition)
- Vol. 36 (3) , 328-329
Late onset of de novo atypical hemolytic–uremic syndrome presented on a simultaneous pancreas and kidney transplant recipient successfully treated with eculizumab
- 1 May 2016
- Published by Elsevier in Nefrología (English Edition)
- Vol. 36 (3) , 328-329
Open AccessLate onset of de novo atypical hemolytic–uremic syndrome presented on a simultaneous pancreas and kidney transplant recipient successfully treated with eculizumab
- Open Access
- 1 May 2016
- Published by Elsevier in Nefrología
- Vol. 36 (3) , 328-329
Late onset of de novo atypical hemolytic–uremic syndrome presented on a simultaneous pancreas and kidney transplant recipient successfully treated with eculizumab
- 1 May 2016
- Published by Elsevier in Nefrología
- Vol. 36 (3) , 328-329
Open AccessLate onset of de novo atypical hemolytic–uremic syndrome presented on a simultaneous pancreas and kidney transplant recipient successfully treated with eculizumab
- 1 October 2015
- Published by Elsevier in Transplantation Proceedings
- Vol. 47 (8) , 2344-2345
Outcomes of Monoclonal Gammopathy of Undetermined Significance in Patients Who Underwent Kidney Transplantation
- 1 October 2015
- Published by Elsevier in Transplantation Proceedings
- Vol. 47 (8) , 2344-2345
Outcomes of Monoclonal Gammopathy of Undetermined Significance in Patients Who Underwent Kidney Transplantation
- 1 October 2015
- Published by Elsevier in Transplantation Proceedings
- Vol. 47 (8) , 2361-2363
Late Onset of Cholesterol Embolism Leading to Graft Failure After Renal Transplantation: Report of Two Cases
- 1 October 2015
- Published by Elsevier in Transplantation Proceedings
- Vol. 47 (8) , 2361-2363
Late Onset of Cholesterol Embolism Leading to Graft Failure After Renal Transplantation: Report of Two Cases
- 1 October 2015
- Published by Elsevier in Transplantation Proceedings
- Vol. 47 (8) , 2357-2360
Nodular Arteriolar Hyalinosis as Histopathologic Hallmark of Calcineurin Inhibitor Nephrotoxicity: Does It Always Have the Same Meaning?
- 1 October 2015
- Published by Elsevier in Transplantation Proceedings
- Vol. 47 (8) , 2357-2360
Nodular Arteriolar Hyalinosis as Histopathologic Hallmark of Calcineurin Inhibitor Nephrotoxicity: Does It Always Have the Same Meaning?
- Open Access
- 1 July 2015
- Published by Elsevier in Nefrología (English Edition)
- Vol. 35 (4) , 413-414
Iliac artery obliteration as a cause of renovascular hypertension in kidney graft recipients: A difficult and uncommon diagnosis
- 1 July 2015
- Published by Elsevier in Nefrología (English Edition)
- Vol. 35 (4) , 413-414
Open AccessIliac artery obliteration as a cause of renovascular hypertension in kidney graft recipients: A difficult and uncommon diagnosis
- Open Access
- 1 July 2015
- Published by Elsevier in Nefrología
- Vol. 35 (4) , 413-414
Obliteración de la arteria ilíaca como causa de hipertensión renovascular en el paciente trasplantado renal, un diagnóstico difícil y poco frecuente
- 1 July 2015
- Published by Elsevier in Nefrología
- Vol. 35 (4) , 413-414
Open AccessObliteración de la arteria ilíaca como causa de hipertensión renovascular en el paciente trasplantado renal, un diagnóstico difícil y poco frecuente
- 12 October 2011
- Published by Frontiers Media SA in Transplant International
- Vol. 25 (1) , 48-55
Renal function and safety in stable kidney transplant recipients converted from immediate-release to prolonged-release tacrolimus
This multicenter, open, phase IIIb study assessed short‐term efficacy, safety and dose adjustments in adult stable renal transplant recipients converted from tacrolimus twice‐daily (BID) to once‐daily (QD). Patients receiving unchanged tacrolimus BID for ≥12 weeks were enrolled, and after 6‐weeks, converted from tacrolimus BID to QD (morning dose) on a 1 : 1 (mg : mg) total daily dose basis, for a further 12 weeks. Primary endpoint: change in steady‐state creatinine clearance between treatment phases. Secondary endpoints: biopsy‐proven acute rejection (BPAR), patient and graft survival, safety. 128 patients enrolled (mean age 48.9 years; time post‐transplant 48.9 months); 91 evaluated for the primary endpoint. Mean total daily dose was 0.06 mg/kg (BID) and 0.07 mg/kg (QD); 79.1% required one/no dose changes post‐conversion to maintain recommended blood‐trough levels; average dose increase was small (0.6–0.7 mg/day) with more dose increases in patients on the lowest tacrolimus BID doses. Renal function remained stable and non‐inferiority of tacrolimus QD against tacrolimus BID was demonstrated. There were no BPAR episodes; patient and graft survival were 100%. Adverse events were few; none led to dose modifications/discontinuation. Tacrolimus BID to tacrolimus QD conversion is straightforward and does not compromise renal function in stable kidney transplant patients in the short term.
- 12 October 2011
- Published by Frontiers Media SA in Transplant International
- Vol. 25 (1) , 48-55
Renal function and safety in stable kidney transplant recipients converted from immediate-release to prolonged-release tacrolimus
This multicenter, open, phase IIIb study assessed short‐term efficacy, safety and dose adjustments in adult stable renal transplant recipients converted from tacrolimus twice‐daily (BID) to once‐daily (QD). Patients receiving unchanged tacrolimus BID for ≥12 weeks were enrolled, and after 6‐weeks, converted from tacrolimus BID to QD (morning dose) on a 1 : 1 (mg : mg) total daily dose basis, for a further 12 weeks. Primary endpoint: change in steady‐state creatinine clearance between treatment phases. Secondary endpoints: biopsy‐proven acute rejection (BPAR), patient and graft survival, safety. 128 patients enrolled (mean age 48.9 years; time post‐transplant 48.9 months); 91 evaluated for the primary endpoint. Mean total daily dose was 0.06 mg/kg (BID) and 0.07 mg/kg (QD); 79.1% required one/no dose changes post‐conversion to maintain recommended blood‐trough levels; average dose increase was small (0.6–0.7 mg/day) with more dose increases in patients on the lowest tacrolimus BID doses. Renal function remained stable and non‐inferiority of tacrolimus QD against tacrolimus BID was demonstrated. There were no BPAR episodes; patient and graft survival were 100%. Adverse events were few; none led to dose modifications/discontinuation. Tacrolimus BID to tacrolimus QD conversion is straightforward and does not compromise renal function in stable kidney transplant patients in the short term.